EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies

Guiwen Liang, Chuli Zhu, Hualin Sun iD, Yanan Ji, Haiyan Jiang iD

Drug Design, Development and Therapy · 2026-09 · Volume 20 · 1-27

DOI: 10.2147/dddt.s638939 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026-09. Verfasst von Guiwen Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People's Republic of China. Hauptthemen laut MEDLINE: Breast Neoplasms, Tumor Microenvironment, Drug Delivery Systems, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer heterogeneity and its complex tumor microenvironment (TME) are key drivers of therapeutic failure and multidrug resistance (MDR). Drug delivery systems (DDS) provide an important approach, but their clinical translation remains limited by biological variability, formulation complexity, and manufacturing challenges. This review delineates the evolution of breast cancer DDS from passive carriers to increasingly functional and responsive platforms, focusing on three core dimensions. First, regarding decisive barriers, we dissect the constraints imposed by the three-dimensional collagen network, pH/glutathione (GSH) gradients, and tumor-associated macrophages (TAMs) on drug penetration. These factors not only act as physical and biochemical obstacles but can also be harnessed as endogenous triggers for responsive design. Second, in terms of diversified platforms, we critically evaluate liposomes, polymeric nanoparticles, hydrogels, extracellular vesicles, and antibody-drug conjugates (ADCs). We highlight the potential of solid lipid nanoparticles to address drug resistance, the development of carrier-free delivery enabled by prodrug self-assembly, and the clinical significance of ADCs (eg, T-DXd) in expanding treatment options for HER2-low breast cancer. Third, we examine inter- and intratumoral heterogeneity, metastatic site-specific delivery barriers in the brain, bone, and lung, the multilayered resistance network from efflux pumps to cancer stem cells, and the sequential barriers nanomedicines must traverse from systemic circulation to intracellular targets. We propose three strategic directions: personalized precision delivery integrating liquid biopsy, organoids, and functional imaging to support patient stratification and treatment adaptation; AI-assisted formulation optimization using machine learning to develop material-structure-function predictive models and support data-driven formulation design; and multi-responsive systems leveraging endogenous signals such as pH, GSH, and enzymes, together with exogenous stimuli including light, magnetism, and ultrasound, for spatiotemporally controlled combination therapy. This review summarizes key considerations from biological barriers to clinical translation, emphasizing that alignment of tumor subtype, metastatic site, microenvironmental characteristics, and patient-specific factors may improve the clinical applicability of drug delivery strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTumor MicroenvironmentDrug Delivery SystemsAntineoplastic AgentsHumansFemaleDrug CarriersAnimalsNanoparticlesDrug Resistance, Neoplasm

Stichwörter der Autor:innen

breast cancerclinical translationdrug delivery systemsmultidrug resistancestimulus-responsive nanoparticlestumor microenvironment

Substanzen

Antineoplastic AgentsDrug Carriers

Autor:innen und Institutionen

  • Department of Emergency Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People's Republic of China.
  • Jiangsu Key Laboratory of Tissue Engineering and Neuroregeneration, Key Laboratory of Neuroregeneration of Ministry of Education, Co-Innovation Center of Neuroregeneration, Medical School of Nantong University, Nantong,…

ORCID-Profile: Hualin Sun, Haiyan Jiang

Zitieren

APA

Liang, G., Zhu, C., Sun, H., Ji, Y., & Jiang, H. (2026). Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies. Drug Design, Development and Therapy, Volume 20, 1-27. https://doi.org/10.2147/dddt.s638939

Vancouver

Liang G, Zhu C, Sun H, Ji Y, Jiang H. Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies. Drug Design, Development and Therapy. 2026;Volume 20:1-27. doi:10.2147/dddt.s638939

BibTeX
@article{Liang2026,
  author = {Liang, Guiwen and Zhu, Chuli and Sun, Hualin and Ji, Yanan and Jiang, Haiyan},
  title = {Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--27},
  doi = {10.2147/dddt.s638939}
}
Kostenlos starten →